Biomerica Secures Medicare Claim Review Pathway for IBS Test, Eyeing Near-Term Revenue
Event summary
- Medicare Administrative Contractor (MAC) confirms individual claim review for Biomerica's inFoods® IBS test, effective immediately.
- Test eligible for $300 CMS payment rate with proper documentation and medical necessity evidence.
- First claims submissions expected soon, targeting revenue from January 1, 2026 service dates.
- Test supported by Level 1 clinical evidence from multicenter trial published in Gastroenterology.
The big picture
This development positions Biomerica to tap into the substantial Medicare-eligible IBS patient population, addressing a significant unmet need in gastrointestinal care. The confirmation of individual claim review aligns with Medicare's standard process for similar diagnostic tests, potentially opening a scalable commercialization pathway. The test's unique CPT code and established CMS payment rate provide a clear reimbursement framework, though claim-by-claim adjudication introduces execution risk.
What we're watching
- Claim Approval Rates
- Whether the MAC will consistently approve claims with proper documentation and how this affects revenue realization.
- Commercial Expansion
- The pace at which Biomerica can establish reimbursement pathways with private insurance companies.
- Market Adoption
- How quickly gastroenterologists will integrate the test into treatment algorithms for IBS patients.
Related topics